These bind to prostate‐specific membrane antigen (PSMA) and exhibit high uptake and prolonged retention selectively in prostatic carcinoma cells and in experimental tumours.4, 5 PSMA is expressed by almost all PCa, particularly in poorly differentiated, metastatic and hormone‐refractory disease.6, 7, 8. Here, FOLH1 is linked to prostate carcinoma.